ReNeuron gets EU stem cell patent:
This article was originally published in Clinica
UK firm ReNeuron has received a European patent covering key neural stem cell lines and their use as a treatment for stroke, Huntington's disease, Alzheimer's disease, traumatic brain injury and Creutzfeldt-Jakob disease. The patent claims also encompass the use of the cell lines in non-therapeutic applications, such as cell-based screens for testing neurological drug candidates. The Guildford, Surrey firm has already filed for approval to begin US clinical studies of its lead ReN001 stem cell therapy for chronic stroke disability. It has also filed patent applications, which are equivalent to the European on, in the US and in other "significant" territories.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.